On June 17, 2025, Mineralys Therapeutics, Inc. reported positive topline results from their Phase 2 Explore-CKD trial, showing that 25 mg of lorundrostat significantly reduced systolic blood pressure and urine albumin-to-creatinine ratio in subjects with hypertension and chronic kidney disease.